1-17 of 17
Christoph Wanner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

14-LB: Finerenone in Patients with CKD and T2D by SGLT2i Treatment: An Analysis of the FIDELIO-DKD Study

PETER ROSSING, RAJIV AGARWAL, STEFAN ANKER, GERASIMOS FILIPPATOS, BERTRAM PITT, LUIS M. RUILOPE, JULIANA C. CHAN, ADRIAAN KOOY, KIERAN MCCAFFERTY, GUNTRAM SCHERNTHANER, CHRISTOPH WANNER, AMER JOSEPH, MARKUS F. SCHEERER, CHARLIE SCOTT, GEORGE BAKRIS
Journal: Diabetes
Diabetes 2021;70(Supplement_1):14-LB
https://doi.org/10.2337/db21-14-LB
Published: 01 June 2021
View article titled, 14-LB: Finerenone in Patients with CKD and T2D by SGLT2i Treatment: An Analysis of the FIDELIO-DKD Study
Meeting Abstracts

790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME

SILVIO E. INZUCCHI, CHRISTOPH WANNER, DAVID H. FITCHETT, BERNARD ZINMAN, STEFAN ANKER, MICHAELA MATTHEUS, OLA VEDIN, STEFAN HANTEL, SØREN S. LUND
Journal: Diabetes
Diabetes 2021;70(Supplement_1):790-P
https://doi.org/10.2337/db21-790-P
Published: 01 June 2021
View article titled, 790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME
Meeting Abstracts

319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial

SABINE KAHL, ANNE PERNILLE OFSTAD, BERNARD ZINMAN, CHRISTOPH WANNER, ELKE SCHUELER, SILVIO E. INZUCCHI, MICHAEL RODEN
Journal: Diabetes
Diabetes 2021;70(Supplement_1):319-OR
https://doi.org/10.2337/db21-319-OR
Published: 01 June 2021
View article titled, 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial
Journal Articles

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Katherine R. Tuttle, Frank C. Brosius, III, Matthew A. Cavender, Paola Fioretto, Kevin J. Fowler, Hiddo J.L. Heerspink, Tom Manley, Darren K. McGuire, Mark E. Molitch, Amy K. Mottl, Leigh Perreault, Sylvia E. Rosas, Peter Rossing, Laura Sola, Volker Vallon, Christoph Wanner, Vlado Perkovic
Journal: Diabetes
Diabetes 2021;70(1):1–16
https://doi.org/10.2337/dbi20-0040
Published: 26 October 2020
View article titled, SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
Open the PDF for SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation in another window
Meeting Abstracts

30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME

MUTHIAH VADUGANATHAN, NAVEED SATTAR, DAVID H. FITCHETT, ANNE PERNILLE OFSTAD, MARTINA BRUECKMANN, JYOTHIS T. GEORGE, SUBODH VERMA, MICHAELA MATTHEUS, CHRISTOPH WANNER, SILVIO E. INZUCCHI, BERNARD ZINMAN, JAVED BUTLER
Journal: Diabetes
Diabetes 2020;69(Supplement_1):30-OR
https://doi.org/10.2337/db20-30-OR
Published: 01 June 2020
View article titled, 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
Meeting Abstracts

28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME

SUBODH VERMA, LAWRENCE A. LEITER, ABHINAV SHARMA, BERNARD ZINMAN, MICHAELA MATTHEUS, DAVID H. FITCHETT, JYOTHIS T. GEORGE, ANNE PERNILLE OFSTAD, CHRISTOPH WANNER, SILVIO E. INZUCCHI
Journal: Diabetes
Diabetes 2020;69(Supplement_1):28-OR
https://doi.org/10.2337/db20-28-OR
Published: 01 June 2020
View article titled, 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME
Meeting Abstracts

1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial

ABHINAV SHARMA, ANNE PERNILLE OFSTAD, TARIQ AHMAD, BERNARD ZINMAN, ISABELLA ZWIENER, DAVID H. FITCHETT, CHRISTOPH WANNER, JYOTHIS T. GEORGE, STEFAN HANTEL, NIHAR DESAI, ROBERT J. MENTZ
Journal: Diabetes
Diabetes 2020;69(Supplement_1):1144-P
https://doi.org/10.2337/db20-1144-P
Published: 01 June 2020
View article titled, 1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial
Meeting Abstracts

1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial

IAN J. NEELAND, BJORN ELIASSON, TAKATOSHI KASAI, NIKOLAUS MARX, BERNARD ZINMAN, SILVIO E. INZUCCHI, CHRISTOPH WANNER, ISABELLA ZWIENER, BRIAN S. WOJECK, HENRY K. YAGGI, ODD ERIK JOHANSEN
Journal: Diabetes
Diabetes 2020;69(Supplement_1):1128-P
https://doi.org/10.2337/db20-1128-P
Published: 01 June 2020
View article titled, 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial
Meeting Abstracts

1224-P: Validation of a New Diabetes Staging System (DSS) for Type 2 Diabetes (T2D) Using Data from Three Cardiovascular Outcomes Trials (CVOTs)

MOAHAD DAR, CHRISTOPH WANNER, NIKOLAUS MARX, ODD ERIK JOHANSEN, ANNE PERNILLE OFSTAD, MICHAELA MATTHEUS, STEFAN KASPERS, JYOTHIS T. GEORGE, JULIO ROSENSTOCK, DARREN K. MCGUIRE, SAMI A. BEG
Journal: Diabetes
Diabetes 2020;69(Supplement_1):1224-P
https://doi.org/10.2337/db20-1224-P
Published: 01 June 2020
View article titled, 1224-P: Validation of a New Diabetes Staging System (DSS) for Type 2 Diabetes (T2D) Using Data from Three Cardiovascular Outcomes Trials (CVOTs)
Meeting Abstracts

131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome

SILVIO E. INZUCCHI, BERNARD ZINMAN, CHRISTOPH WANNER, DAVID H. FITCHETT, STEFAN ANKER, STUART POCOCK, STEFAN KASPERS, JYOTHIS T. GEORGE, ODD ERIK JOHANSEN, WAHEED JAMAL, STEFAN HANTEL, SØREN S. LUND
Journal: Diabetes
Diabetes 2020;69(Supplement_1):131-LB
https://doi.org/10.2337/db20-131-LB
Published: 01 June 2020
View article titled, 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome
Meeting Abstracts

132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects

SILVIO E. INZUCCHI, BETTINA J. KRAUS, MATTHEW R. WEIR, GEORGE BAKRIS, MICHAELA MATTHEUS, DAVID CHERNEY, NAVEED SATTAR, HIDDO L. HEERSPINK, IVANA RITTER, MAXIMILIAN VON EYNATTEN, BERNARD ZINMAN, CHRISTOPH WANNER, AUDREY KOITKA-WEBER
Journal: Diabetes
Diabetes 2020;69(Supplement_1):132-LB
https://doi.org/10.2337/db20-132-LB
Published: 01 June 2020
View article titled, 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects
Meeting Abstracts

248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial

SILVIO E. INZUCCHI, BERNARD ZINMAN, JYOTHIS GEORGE, MICHAELA MATTHEUS, MAXIMILIAN VON EYNATTEN, CHRISTOPH WANNER, SIBYLLE HAUSKE
Journal: Diabetes
Diabetes 2019;68(Supplement_1):248-OR
https://doi.org/10.2337/db19-248-OR
Published: 01 June 2019
View article titled, 248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial
Meeting Abstracts

159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME

BERNARD ZINMAN, DAVID H. FITCHETT, MICHAELA MATTHEUS, CHRISTOPH WANNER, JYOTHIS T. GEORGE, OLA VEDIN, SILVIO E. INZUCCHI, ODD ERIK JOHANSEN
Journal: Diabetes
Diabetes 2019;68(Supplement_1):159-LB
https://doi.org/10.2337/db19-159-LB
Published: 01 June 2019
View article titled, 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME
Meeting Abstracts

388-P: Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial

JULIO ROSENSTOCK, STEVEN E. KAHN, ODD ERIK JOHANSEN, MARK E. COOPER, NIKOLAUS MARX, JOHN H. ALEXANDER, ROBERT D. TOTO, CHRISTOPH WANNER, EGON PFARR, SVEN SCHNAIDT, JYOTHIS GEORGE, MAXIMILIAN VON EYNATTEN, DARREN K. MCGUIRE, VLADO PERKOVIC, BERNARD ZINMAN
Journal: Diabetes
Diabetes 2019;68(Supplement_1):388-P
https://doi.org/10.2337/db19-388-P
Published: 01 June 2019
View article titled, 388-P: Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial
Meeting Abstracts

432-P: Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease

NIKOLAUS MARX, DARREN K. MCGUIRE, ODD ERIK JOHANSEN, JULIO ROSENSTOCK, STEVEN E. KAHN, MARK E. COOPER, ROBERT D. TOTO, CHRISTOPH WANNER, EGON PFARR, SVEN SCHNAIDT, JYOTHIS GEORGE, MAXIMILIAN VON EYNATTEN, VLADO PERKOVIC, BERNARD ZINMAN, JOHN H. ALEXANDER
Journal: Diabetes
Diabetes 2019;68(Supplement_1):432-P
https://doi.org/10.2337/db19-432-P
Published: 01 June 2019
View article titled, 432-P: Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease
Meeting Abstracts

19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME

SILVIO E. INZUCCHI, KAMLESH KHUNTI, DAVID H. FITCHETT, CHRISTOPH WANNER, MICHAELA MATTHEUS, JYOTHIS GEORGE, ANNE PERNILLE OFSTAD, BERNARD ZINMAN
Journal: Diabetes
Diabetes 2019;68(Supplement_1):19-LB
https://doi.org/10.2337/db19-19-LB
Published: 01 June 2019
View article titled, 19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME
Meeting Abstracts

Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c

CHRISTOPH WANNER, MARK E. COOPER, SILVIO INZUCCHI, BERNARD ZINMAN, UWE HEHNKE, MAXIMILIAN VON EYNATTEN, AUDREY KOITKA-WEBER
Journal: Diabetes
Diabetes 2018;67(Supplement_1):524-P
https://doi.org/10.2337/db18-524-P
Published: 01 July 2018
View article titled, Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c